Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the <scp>TANDEM</scp> study
The use of atogepant 60 mg QD for the preventive treatment of EM and ubrogepant 100 mg PRN for the acute treatment of migraine over the 12-week open-label concomitant use treatment period was safe and well tolerated. The overall safety results were consistent with the known safety profiles of atogepant and ubrogepant when used alone and no new safety signals were identified.
Authors
- Brad Klein (ORCID: https://orcid.org/0000-0002-8278-0092)
- Rosa De Abreu Ferreira
- Andrew Blumenfeld (ORCID: https://orcid.org/0000-0003-0851-4914)
- Laszlo Mechtler (ORCID: https://orcid.org/0000-0002-6105-9159)
- Jessica Ailani (ORCID: https://orcid.org/0000-0001-8106-4927)
- Joel M. Trugman (ORCID: https://orcid.org/0000-0002-2376-8878)
- Jonathan H. Smith (ORCID: https://orcid.org/0000-0002-0295-6773)
- Elimor Brand‐Schieber
- Yizeng He (ORCID: https://orcid.org/0009-0008-6353-8437)
- Richard Lipton
Institutions
- Albert Einstein College of Medicine (US)
- Georgetown University (US)
- MedStar Georgetown University Hospital (US)
- Abington Memorial Hospital (US)
- AbbVie (United States) (US)
- Dent Neurologic Institute (US)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2024-11-21
- DOI
- https://doi.org/10.1111/head.14871
- Citations
- 9
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.47
Funders
- AbbVie